Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma
Authors:
Open Access
- 21 November 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (23) , 15642-15662
Abstract
Indoleamine 2,3-dioxygenase 1 (IDO1) is a potent immunosuppressive enzyme that inhibits the antitumor immune response through both tryptophan metabolism and non-enzymatic functions. To date, most IDO1-targeted approaches have focused on inhibiting tryptophan metabolism. However, this class of drugs has failed to improve the overall survival of patients with cancer. Here, we developed and characterized proteolysis targeting chimeras (PROTACs) that degrade the IDO1 protein. IDO1-PROTACs were tested for their effects on IDO1 enzyme and non-enzyme activities. After screening a library of IDO1-PROTAC derivatives, a compound was identified that potently degraded the IDO1 protein through cereblon-mediated proteasomal degradation. The IDO1-PROTAC: (i) inhibited IDO1 enzyme activity and IDO1-mediated NF-κB phosphorylation in cultured human glioblastoma (GBM) cells, (ii) degraded the IDO1 protein within intracranial brain tumors in vivo, and (iii) mediated a survival benefit in mice with well-established brain tumors. This study identified and characterized a new IDO1 protein degrader with therapeutic potential for patients with glioblastoma.Keywords
Funding Information
- National Cancer Institute (P50CA221747)
- National Institute of Neurological Disorders and Stroke (R01NS097851, R01NS102669, R01NS113425)
- Chicago Biomedical Consortium (DF-008)
- National Institute on Aging (K02AG068617)
- American Cancer Society (RSG-21-058-01-CCE)
- 5 for the Fight
- Glioblastoma Foundation
- Lou Malnati Brain Tumor Institute
- BrainUp (2136)
This publication has 55 references indexed in Scilit:
- Targeting Tregs in Malignant Brain Cancer: Overcoming IDOFrontiers in Immunology, 2013
- IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts SurvivalClinical Cancer Research, 2012
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptorNature, 2011
- Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumorsNeuro-Oncology, 2011
- Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cellsNature Immunology, 2011
- Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancerCytokine & Growth Factor Reviews, 2010
- Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinomaGynecologic Oncology, 2009
- Indoleamine 2,3-dioxygenase–expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cellsBlood, 2009
- Microcalorimetry of biological macromoleculesBiophysical Chemistry, 2007
- The two NF-κB activation pathways and their role in innate and adaptive immunityTrends in Immunology, 2004